Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | ALPL | P05186 | 12/20 | 0.61 |
| ▸ | CA12 | O43570 | 5/20 | 0.61 |
| ▸ | RPA1 | P27694 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 3/20 | 0.56 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.54 |
| ▸ | HPGDS | O60760 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MARS1 | P56192 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL222852 | 0.83 | TP53 (0.74) | TP53ALPLCA12RPA1CA9 | |
| Hydrochloric Acid SCHEMBL27639048 | 0.81 | TP53 (0.72) | TP53ALPLCA12RPA1CA9 | |
| SCHEMBL726574 | 0.79 | TP53 (1.00) | TP53ALPLCA12RPA1CA9 | |
| SCHEMBL1816813 | 0.79 | TP53 (0.73) | TP53ALPLCA12RPA1CA9 | |
| SCHEMBL31412612 | 0.78 | ALPL (0.66) | TP53ALPLCA12CA9HPGDS | |
| SCHEMBL27639046 | 0.76 | ALPL (0.63) | TP53ALPLCA12RPA1CA9 | |
| SCHEMBL23780339 | 0.76 | TP53 (0.64) | TP53ALPLCA12RPA1CA9 | |
| SCHEMBL1414100 | 0.76 | ALPL (1.00) | TP53ALPLCA12RPA1CA9 | |
| SCHEMBL3447352 | 0.75 | ALPL (1.00) | TP53ALPLCA12RPA1CA9 | |
| SCHEMBL645330 | 0.75 | ALPL (1.00) | TP53ALPLCA12RPA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025045746-A1 | PYRAZOLE DERIVATIVES AS SARM1 INHIBITORS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2025-03-06 | — | — | WO | disclosed |